@ARTICLE{
author={Braten Line Skute,Haslemo Tore,Jukic Marin M,Ivanov Maxim,Ingelman-Sundberg Magnus,Molden Espen,Kringen Marianne Kristiansen},
year={2021},
title={A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram},
journal={CLINICAL PHARMACOLOGY & THERAPEUTICS},
volume={110},
number={3},
pages={786-793},
document_type={Article},
} 

@ARTICLE{
author={Braten Line Skute,Haslemo Tore,Jukic Marin M,Ingelman-Sundberg Magnus,Molden Espen,Kringen Marianne Kristiansen},
year={2020},
title={Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients},
journal={NEUROPSYCHOPHARMACOLOGY},
volume={45},
number={3},
pages={570-576},
document_type={Article},
} 

@ARTICLE{
author={Jukic Marin M,Smith Robert Lovsletten,Haslemo Tore,Molden Espen,Ingelman-Sundberg Magnus},
year={2019},
title={Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study},
journal={LANCET PSYCHIATRY},
volume={6},
number={5},
pages={418-426},
document_type={Article},
} 

@ARTICLE{
author={Haslemo Tore,Eliasson Erik,Jukic Marin M,Ingelman-Sundberg Magnus,Molden Espen},
year={2019},
title={Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients},
journal={BRITISH JOURNAL OF CLINICAL PHARMACOLOGY},
volume={85},
number={1},
pages={194-201},
document_type={Article},
} 

@ARTICLE{
author={Jukic Marin M,Haslemo Tore,Molden Espen,Ingelman-Sundberg Magnus},
year={2018},
title={Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients},
journal={AMERICAN JOURNAL OF PSYCHIATRY},
volume={175},
number={5},
pages={463-470},
document_type={Article},
}